X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, Premier will have access of EXPAREL (bupivacaine), a single-dose local and regional analgesic that provides prolonged postsurgical pain control while reducing reliance on opioids.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pacira BioSciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 07, 2024
Details:
Under the agreement, Trevena awarded Premier to take advantage of special pricing for Olinvyk. Olinvyk contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 04, 2023
Details:
Under the collaboration, Endo's Par Sterile Products business will supply Pitocin® (oxytocin injection, USP) vials through Premier's ProvideGx® and PremierProRx® programs. Pitocin® is used to induce labor in pregnant women.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Pitocin
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Endo International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 17, 2023
Details:
Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Meitheal Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 18, 2020
Details:
The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
Lead Product(s): Meloxicam
Therapeutic Area: Neurology Product Name: Anjeso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baudax Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 25, 2020
Details:
Under terms of this partnership, Somerset Pharma will supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory infections, a common complication associated with COVID-19, to Premier.
Lead Product(s): Sulfamethoxazole,Trimethoprim
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Somerset Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 04, 2020
Details:
Premier through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.
Lead Product(s): Propofol
Therapeutic Area: Neurology Product Name: Diprivan
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 13, 2020
Details:
Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.
Lead Product(s): IBUTILIDE FUMARATE
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
